Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | DHPS | P49366 | 3/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1601015 | 0.86 | ALK (0.57) | CYP2A6ALKGLO1CYP11B1CYP11B2 | |
| SCHEMBL14387472 | 0.86 | GSK3A (0.47) | GSK3AGSK3BALKBRD4ALDH1A1 | |
| SCHEMBL3602326 | 0.84 | GSK3A (0.48) | GSK3AGSK3BALKBRD4ALDH1A1 | |
| SCHEMBL1601054 | 0.83 | ALK (0.47) | GSK3AGSK3BALKBRD4SMN1; SMN2 | |
| SCHEMBL1600959 | 0.83 | GSK3A (0.44) | GSK3AGSK3BALKBRD4ALDH1A1 | |
| SCHEMBL1601434 | 0.83 | ALK (0.48) | CYP2A6ALKL3MBTL1CYP11B1CYP11B2 | |
| SCHEMBL1602137 | 0.83 | ALK (0.52) | GSK3AGSK3BALKBRD4ALDH1A1 | |
| SCHEMBL19908199 | 0.82 | ALK (0.50) | GSK3AGSK3BALKBRD4 | |
| SCHEMBL1601722 | 0.81 | BRD4 (0.45) | GSK3AGSK3BALKBRD4 | |
| SCHEMBL1601579 | 0.81 | ALK (0.51) | GSK3AGSK3BALKBRD4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | claimed |
| US-7601716-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2009-10-13 | — | — | US | claimed |
| EP-2091951-A2 | PYRIDO[2,3-B]PYRAZINE AND[1,8]-NAPHTYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2009-08-26 | — | — | EP | claimed |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | CEPHALON, INC. (US) | 2008-02-07 | — | — | US | claimed |
| WO-2007130468-A2 | PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-8080561-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080561-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080561-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110160204-A1 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160204-A1 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7601716-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601716-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2091951-A2 | PYRIDO[2,3-B]PYRAZINE AND[1,8]-NAPHTYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | CEPHALON, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | CEPHALON, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | CEPHALON, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2007130468-A2 | PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130468-A2 | PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160204-A1 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS | ALK, MET, RET | GSK3A 1313/4885GSK3B 1084/4885CYP2E1 1000/4885 |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | ALK, MET, RET | GSK3A 1313/4885GSK3B 1084/4885CYP2E1 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.